DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cervarix (Human Papillomavirus Vaccine) - Summary



CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types 16 and 18.

CERVARIX® is indicated for the following:

CERVARIX® is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18 [see Clinical Studies] :

  • cervical cancer,
  • cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and
  • cervical intraepithelial neoplasia (CIN) grade 1.

CERVARIX is approved for use in females 10 through 25 years of age.

Limitations of Use and Effectiveness

CERVARIX does not provide protection against disease due to all HPV types [see Clinical Studies].

CERVARIX has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a woman has previously been exposed through sexual activity [see Clinical Studies].

Females should continue to adhere to recommended cervical cancer screening procedures [see Patient Counseling Information].

Vaccination with CERVARIX may not result in protection in all vaccine recipients.

See all Cervarix indications & dosage >>


Media Articles Related to Cervarix (Human Papillomavirus Vaccine)

Flu vaccination rates among health care workers climb with mandatory policy
Source: Flu / Cold / SARS News From Medical News Today [2014.09.09]
Hospitals can greatly improve their flu vaccination rate among health care workers by using a mandatory employee vaccination policy, according to a Henry Ford Health System study.

HPV vaccination program in Australia leads to 61 percent fall in female genital warts
Source: Sexual Health / STDs News From Medical News Today [2014.09.09]
GPs in Australia are managing 61 per cent less cases of genital warts among young women since the introduction of the national human papillomavirus (HPV) vaccination program, a new study from the...

Influenza vaccination of pregnant women protects mothers and their babies
Source: Flu / Cold / SARS News From Medical News Today [2014.09.08]
A study showing that the influenza vaccination of pregnant HIV-uninfected and HIV-infected women is safe and protects the women against confirmed influenza illness, has been published by...

Vaccination against H5N1 flu virus generates broadly reactive antibodies
Source: Bird Flu / Avian Flu News From Medical News Today [2014.08.27]
Vaccine researchers have developed a strategy aimed at generating broadly cross-reactive antibodies against the influenza virus: embrace the unfamiliar.

Some mothers-to-be opt out of vaccination for flu
Source: Flu / Cold / SARS News From Medical News Today [2014.08.20]
Both mother and fetus are at increased risk for complications of flu infection during pregnancy.

more news >>

Published Studies Related to Cervarix (Human Papillomavirus Vaccine)

Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. [2012]
The exploratory immunogenicity objective of this analysis was to characterize the titer of vaccine human papillomavirus (HPV)-type immunoglobulins in both peripartum maternal blood and the cord blood of infants born to women who received blinded therapy.

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. [2011.03]
BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months)... CONCLUSIONS: The third dose of the HPV-16/18 vaccine can be administered any time between 6 and 12 months after the first dose, with adequate immunogenicity and a clinically acceptable safety profile.

Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males. [2011]
The quadrivalent HPV types 6, 11, 16, 18 vaccine (Gardasil®) is a recombinant vaccine comprising purified virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18. The vaccine was highly immunogenic... The most common adverse events reported were injection-site related, and most of these were of mild to moderate severity.

Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. [2011]
Efficacy, immunogenicity and tolerability of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine were evaluated in Japanese women aged 20-25 years, for which results have been reported previously. We analyzed the baseline data from that study and report the prevalence rates of HPV infection in young healthy Japanese women...

Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. [2010.08]
The human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine has been demonstrated to be highly efficacious and immunogenic with a favorable safety profile... In conclusion, the HPV-16/18 AS04-adjuvanted vaccine is shown to be highly immunogenic and generally well-tolerated in Korean girls aged 10-14 yr.

more studies >>

Clinical Trials Related to Cervarix (Human Papillomavirus Vaccine)

Drug Use Investigation of Cervarix® [Not yet recruiting]

Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada [Recruiting]
This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i. e. women with last menstrual period between 30 days before and 90 days after any dose of CERVARIX, when compared to a Non-exposed vaccinated cohort, i. e. women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose.

Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls [Recruiting]
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.

Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination [Recruiting]
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females [Not yet recruiting]
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix™ in HIV infected females aged 15 to 25 years as compared to Merck's HPV vaccine (Gardasil®). For comparative purposes, a group of HIV negative females will also be evaluated. All subjects will receive the HPV vaccine (either Cervarix™ or Gardasil®) according to a three-dose schedule (Day 0, Week 6, Month 6).

The protocol posting has been updated following Protocol update in April 2010. The section impacted is eligibility criteria.

more trials >>

Page last updated: 2014-09-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014